Novartis’s Multiple Sclerosis Pill, a Likely Blockbuster, Gets FDA Approval
After a long wait, the FDA has OK’d Novartis’s Gilenya as a first-line treatment for relapsing forms of multiple sclerosis — the disease’s most common form. MS affects over 400,000 Americans and more than 2.1 million people wo…